^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Published date:
11/06/2019
Excerpt:
...patients with TP53 mutation were more likely to have a low CR rate after CAR-T treatment [OR=4.511(95%CI 1.295-16.895)].
DOI:
https://doi.org/10.1182/blood-2019-125503
Source:
Title:
Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations
Published date:
11/06/2019
Excerpt:
In this ongoing trial, 11 R/R AL patients with TP53 alterations (10 with TP53 mutations and 1 with TP53 deletions) including 2 relapsed after allo- allogeneic hematopoietic stem cell transplantation were included to evaluate the efficacy and safety of CAR-T therapy....9 patients were diagnosed with B-ALL...With a median (range) dose of 1×107/kg (0.1-1.5×107/kg) CAR-T cells, we observed a high response rate with 10/11 (90.9%) evaluated R/R patients achieved complete remission (CR) and 9/11 (81.8%) patients achieved molecular CR (mCR).
DOI:
https://doi.org/10.1182/blood-2019-128013
